Article
Multiple-dose regimen safe for neovascular AMD
Author(s):
Fort Lauderdale, FL-In a phase I, multicenter, randomized trial, the anti-VEGF antibody fragment rhuFab V2 was shown to be safe and well-tolerated in eyes with neovascular age-related macular degeneration (AMD), according to Philip J. Rosenfeld, MD, PhD.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
